head and neck squamous cell cancer
Conditions
Interventions
None listed
Sponsors
Clinical Research Support Center Kyushu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients who are eligible for nivolumab for head and neck cancer cases with recurrence or distant metastasis. Primary site: nasal sinus, oral cavity, nasopharynx, oropharynx (p16 positive), oropharynx (p16 negative), hypopharynx, larynx (upper glottic, lower glottic) 2.Patients who are diagnosed histologically as squamous cell carcinoma. 3.Patients aged 20 and over at the time of signing the Informed Consent Form. 4.Patients with target lesion by RECIST on imaging examination within 28 days before enrollment. As basics,it is a contrast CT examination. However, if contrast-enhanced CT examination is impossible or inappropriate due to contrast agent allergy, renal dysfunction, or problems in image evaluation, simple CT, contrast-enhanced MRI, or simple MRI can be substituted. 5.Patients who fully understand this research plan and have obtained written consent.
Exclusion criteria
Exclusion criteria: 1.Patients who have been given immune checkpoint inhibitors in the past. 2.Patients with ECOG Performance Status 3 or 4 3.Patients under tumor immunotherapy or with plan to be co-administered with other antineoplastic agents. 4.Patients with active double cancer excluding CIS and endoscopically treatable early esophagus cancer. 5.patients judged inappropriate by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year survival rate | — |
Countries
Japan
Contacts
Public ContactSatoshi Toh
National Hospital Organization Kyushu Cancer Center Department of Head and Neck Surgery
Outcome results
None listed